- Home
- TOP vs STTK Comparison
TOP vs STTK Comparison
Compare TOP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- STTK
- Stock Information
- Founded
- TOP 2015
- STTK 2016
- Country
- TOP Hong Kong
- STTK United States
- Employees
- TOP N/A
- STTK N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- TOP Finance
- STTK Health Care
- Exchange
- TOP Nasdaq
- STTK Nasdaq
- Market Cap
- TOP 57.8M
- STTK 56.8M
- IPO Year
- TOP 2022
- STTK 2020
- Fundamental
- Price
- TOP $1.40
- STTK $1.37
- Analyst Decision
- TOP
- STTK Hold
- Analyst Count
- TOP 0
- STTK 3
- Target Price
- TOP N/A
- STTK $2.00
- AVG Volume (30 Days)
- TOP 56.6K
- STTK 131.9K
- Earning Date
- TOP 03-04-2025
- STTK 03-03-2025
- Dividend Yield
- TOP N/A
- STTK N/A
- EPS Growth
- TOP N/A
- STTK N/A
- EPS
- TOP N/A
- STTK N/A
- Revenue
- TOP $2,730,890.00
- STTK $6,435,000.00
- Revenue This Year
- TOP N/A
- STTK $313.04
- Revenue Next Year
- TOP N/A
- STTK N/A
- P/E Ratio
- TOP N/A
- STTK N/A
- Revenue Growth
- TOP N/A
- STTK 382.75
- 52 Week Low
- TOP $1.25
- STTK $0.94
- 52 Week High
- TOP $3.30
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- TOP 43.79
- STTK 60.23
- Support Level
- TOP $1.39
- STTK $1.21
- Resistance Level
- TOP $1.44
- STTK $1.36
- Average True Range (ATR)
- TOP 0.05
- STTK 0.10
- MACD
- TOP 0.00
- STTK 0.01
- Stochastic Oscillator
- TOP 60.61
- STTK 90.00
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.